ShareValue.ai

ShareValue scores for PODD: Valuation 34, Quality 57, Growth 78, Health 60.

PODD
NASDAQ

Insulet Corporation

$158.25(+2.88%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-4% to 11%
Valuation
34
Overvalued
Price vs Value
Quality
57
Moderate
Business Strength
Growth
78
Strong
Revenue & Earnings
Health
60
Moderate
Financial Stability
Momentum
5
Bearish
Price Trend

Company Details

About

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Score Analysis

AI Investment Thesis

Data as of:Jun 29, 2026
|
Last calculated:Jun 29, 2026